Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study

Abstract

Bevacizumab seems to be well tolerated and active in the second- and third-line treatment of patients with EOC/PPC and merits phase III investigation.

Phase II Study of Intraperitoneal Paclitaxel Plus Cisplatin and Intravenous Paclitaxel Plus Bevacizumab As Adjuvant Treatment of Optimal Stage II/III Epithelial Ovarian Cancer

“…[7][8][9] Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor 10 and has activity against recurrent ovarian cancer. 11,12 Its role in adjuvant therapy is under investigation; the GOG-218 and ICON7 trials evaluated bevacizumab in combination with adjuvant IV carboplatin ϩ paclitaxel. 13,14 Both studies showed a small improvement in progression-free survival (PFS) among patients assigned to bevacizumab treatment.…”

Anti-angiogenic therapy in ovarian cancer: a great expectation to be confirmed

“…The GOG-170D trial showed that bevacizumab is an active drug in recurrent ovarian carcinoma, achieving a response rate of 21% and more importantly a median progression-free survival of 4.7 months, which was signifi cantly higher than previously observed in comparison to the median PFS obtained in historical GOG phase II trials with new drugs in recurrent ovarian carcinoma [7]. The toxicity of bevacizumab in this trial was not different from the expected hypertension and a low incidence of severe proteinuria or thrombotic events.…”

Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma—Mechanistics, review of phase III randomized clinical trials, and regulatory implications

“…These changes are hypothesized to result in improved delivery of oxygen, nutrients, and cytotoxic chemotherapy to the tumor [43]. Table 1 details notable phase 2 studies of anti-angiogenesis therapy in EOC [44][45][46][47][48][49][50][51][52][53][54]. Of the 6 molecules studied, 5 have been advanced to the phase 3 arena.…”

“…OCEANS, an industry sponsored trial, evaluated the efficacy and safety of bevacizumab in the treatment of patients with recurrent, platinum sensitive ovarian cancer [61]. This trial was initiated in response to GOG 170D, which indicated response to single agent bevacizumab in platinum sensitive and platinum refractory disease [44]. Rates of neutropenia and febrile neutropenia were similar in both arms.…”